|  |  | 

India Top Headlines

Covaxin Was Found To Neutralize Covid-19 Variant 617: Dr. Fauci | India News


WASHINGTON: Covaxin, India’s homegrown Covid-19 vaccine, has been found to neutralize variant 617 of the deadly virus, White House chief medical adviser and top US pandemic expert Dr. Anthony Fauci.
Fauci spoke to reporters during a conference call on Tuesday.
“This is something that we are still getting data on on a daily basis. But the most recent data was Covid-19 convalescent serum cases and people who received the vaccine used in India, Covaxin. It was found to neutralize all 617 variants, “he said.
“So despite the real difficulty that we are seeing in India, vaccination could be a very, very important antidote to this,” Fauci added.
On Tuesday, The New York Times said that Covaxin works by teaching the immune system to produce antibodies against the SARS-CoV-2 coronavirus. Antibodies stick to viral proteins, such as so-called spike proteins, that dot their surface.
Developed by Bharat Biotech in association with the National Institute of Virology and the Indian Council for Medical Research, Covaxin was approved for emergency use on January 3. The results of the trial later showed the vaccine to be 78 percent effective.
Responding to a question, Dr. Andy Slavitt, the White House’s Senior Covid-19 Response Advisor, said that a strike team from the Center for Disease Control and Prevention is heading to India to help coordinate this response.
“We are making sure to locate some of the raw materials needed to create more vaccines in India, which I think will be an important help there,” he said.
“We support the country of India during this very difficult and tragic wave. We are working to deploy resources and supplies, including therapeutic products, rapid test kits, ventilators, PPE and raw materials, which are needed to make vaccines in India, and the CDC, which has a long history of working with and in India on public health measures, will deploy a strike team to the country to support public health efforts there, “Slavitt said.
Given the strong portfolio of approved, highly effective and safe vaccines here in the United States, the administration is looking at options to share AstraZeneca vaccines with other countries as they become available.
This should amount to around 60 million doses over the next two months, he added.
“The AstraZeneca vaccine is highly safe and effective, and it is approved in many parts of the world, and since it is not approved for use in the US, we do not need to use the AstraZeneca vaccine here for the next several months.” Slavitt said. .
“We have a sufficient supply of vaccines from Pfizer, Moderna and Johnson & Johnson to meet our needs in the United States,” he added.

Original source